Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen ...

Summary by Post Register
OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer development program and outlined a series of anticipated milestones that position the…

1 Articles

Post RegisterPost Register
Center

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen ...

OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer development program and outlined a series of anticipated milestones that position the…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Post Register broke the news on Wednesday, June 24, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Ocala icon

Ocala

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal